• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates.

作者信息

Szuber Natasha, Lavu Sravanthi, Mudireddy Mythri, Nicolosi Maura, Penna Domenico, Vallapureddy Rangit R, Lasho Terra L, Finke Christy, Hanson Curtis A, Ketterling Rhett P, Pardanani Animesh, Gangat Naseema, Tefferi Ayalew

机构信息

Division of Hematology, Department of Internal and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.

Division of Hematopathology, Department of Internal and Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.

出版信息

Blood Cancer J. 2018 Nov 19;8(12):118. doi: 10.1038/s41408-018-0157-5.

DOI:10.1038/s41408-018-0157-5
PMID:30455425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6242882/
Abstract
摘要

相似文献

1
Serum erythropoietin levels in essential thrombocythemia: phenotypic and prognostic correlates.原发性血小板增多症患者的血清促红细胞生成素水平：表型及预后相关性
Blood Cancer J. 2018 Nov 19;8(12):118. doi: 10.1038/s41408-018-0157-5.
2
Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis.真性红细胞增多症/原发性血小板增多症后骨髓纤维化患者应用原发性骨髓纤维化预后评分的差异。
Haematologica. 2016 Oct;101(10):e405-e406. doi: 10.3324/haematol.2016.149013. Epub 2016 Jun 27.
3
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化患者的表型和基因型的性别效应：MYSEC项目的结果
Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x.
4
Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).慢性骨髓增殖性疾病（MPD）、原发性血小板增多症（ET）、真性红细胞增多症（PV）和慢性特发性骨髓纤维化（CIMF）的现行诊断标准。
Pathol Biol (Paris). 2007 Mar;55(2):92-104. doi: 10.1016/j.patbio.2006.06.002. Epub 2006 Aug 21.
5
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化患者的表型变异性与从真性红细胞增多症和原发性血小板增多症进展的时间相关。
Leuk Res. 2018 Jun;69:100-102. doi: 10.1016/j.leukres.2018.04.012. Epub 2018 Apr 23.
6
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化中细胞遗传学异常的价值：MYSEC项目研究
Haematologica. 2018 Sep;103(9):e392-e394. doi: 10.3324/haematol.2017.185751. Epub 2018 Apr 5.
7
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.一个临床-分子预后模型，用于预测真性红细胞增多症后和特发性血小板增多症后骨髓纤维化患者的生存情况。
Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31.
8
Cause-specific mortality following polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the US population, 2001-2017.2001 - 2017年美国人群真性红细胞增多症、原发性血小板增多症和原发性骨髓纤维化后的特定病因死亡率。
Am J Hematol. 2021 Dec 1;96(12):E451-E454. doi: 10.1002/ajh.26362. Epub 2021 Oct 11.
9
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.原发性血小板增多症后和真性红细胞增多症后的患者与原发性骨髓纤维化患者有所不同。
Leuk Res. 2017 Aug;59:110-116. doi: 10.1016/j.leukres.2017.06.001. Epub 2017 Jun 2.
10
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.真性红细胞增多症、原发性血小板增多症以及原发性骨髓纤维化伴或不伴JAK2 V617F突变时的巨核细胞形态及临床参数
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.

引用本文的文献

1
Interaction of S100A6 Protein with the Four-Helical Cytokines.S100A6 蛋白与四螺旋细胞因子的相互作用。
Biomolecules. 2023 Sep 4;13(9):1345. doi: 10.3390/biom13091345.
2
Polycythemia vera: historical oversights, diagnostic details, and therapeutic views.真性红细胞增多症：历史的忽视、诊断的细节和治疗的观点。
Leukemia. 2021 Dec;35(12):3339-3351. doi: 10.1038/s41375-021-01401-3. Epub 2021 Sep 3.

本文引用的文献

1
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
2
The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.血清促红细胞生成素水平及JAK2 V617F等位基因负荷在真性红细胞增多症诊断中的作用。
Br J Haematol. 2014 Nov;167(3):411-7. doi: 10.1111/bjh.13047. Epub 2014 Jul 18.
3
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
JAK2 或 CALR 突变状态定义了具有显著不同临床过程和结局的特发性血小板增多症亚型。
Blood. 2014 Mar 6;123(10):1544-51. doi: 10.1182/blood-2013-11-539098. Epub 2013 Dec 23.
4
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.一种用于预测 867 例世界卫生组织定义的原发性血小板增多症患者诊断时生存情况的预后模型：国际骨髓纤维化研究和治疗工作组的研究。
Blood. 2012 Aug 9;120(6):1197-201. doi: 10.1182/blood-2012-01-403279. Epub 2012 Jun 26.
5
Hydroxyurea therapy increases plasma erythropoietin in patients with essential thrombocythaemia or polycythaemia vera.羟基脲疗法可提高原发性血小板增多症或真性红细胞增多症患者的血浆促红细胞生成素水平。
Clin Lab Haematol. 2006 Aug;28(4):233-6. doi: 10.1111/j.1365-2257.2006.00789.x.
6
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.基于JAK2 V617F突变状态的原发性血小板增多症亚型定义及其与真性红细胞增多症的关系：一项前瞻性研究。
Lancet. 2005 Dec 3;366(9501):1945-53. doi: 10.1016/S0140-6736(05)67785-9.
7
Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis.血清促红细胞生成素水平在真性红细胞增多症患者中的诊断价值。
Haematologica. 2004 Oct;89(10):1194-8.
8
The relation between plasma thrombopoietin and erythropoietin concentrations in polycythaemia vera and essential thrombocythaemia.真性红细胞增多症和原发性血小板增多症中血浆血小板生成素与促红细胞生成素浓度之间的关系。
Leuk Lymphoma. 2001 May;41(5-6):579-84. doi: 10.3109/10428190109060348.
9
New automated chemiluminescent assay for erythropoietin.新型促红细胞生成素自动化化学发光检测法
J Clin Lab Anal. 2000;14(6):271-3. doi: 10.1002/1098-2825(20001212)14:6<271::aid-jcla4>3.0.co;2-8.
10
Plasma erythropoietin in essential thrombocythaemia: at diagnosis and in response to myelosuppressive treatment.真性红细胞增多症中的血浆促红细胞生成素：诊断时及对骨髓抑制治疗的反应
Leuk Lymphoma. 2000 Jun;38(1-2):113-20. doi: 10.3109/10428190009060324.